$MRNA 40 percent of the P1 participants reported fever after the second 100 microgram injection. I understand that there are no "trial-limiting safety concerns", but when you compare this to Sanofi's fluzone quadrivalent (.4 percent experiencing fever)...seasonal flu that also kills... How is this gonna be received by the public..if in fact it is approved? Those were healthy people in P1, and younger than the target market that desperately needs this Vax. Thoughts?